Literature DB >> 24237367

Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses.

Jeremy A Rassen1, Sebastian Schneeweiss.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 24237367     DOI： 10.2217/cer.12.12

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN： 2042-6305            Impact factor:   1.744


× No keyword cloud information.
  3 in total

1.  Current use of routinely collected health data to complement randomized controlled trials: a meta-epidemiological survey.

Authors:  Lars G Hemkens; Despina G Contopoulos-Ioannidis; John P A Ioannidis
Journal:  CMAJ Open       Date:  2016-04-06

2.  Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.

Authors:  Emily Nash Smyth; Julie Beyrer; Kimberly R Saverno; Elizabeth Hadden; Hamed Abedtash; Angelo DeLuca; Garreth W Lawrence; Sarah Rybowski
Journal:  Drugs Real World Outcomes       Date:  2022-09-12

3.  On the use of propensity scores in case of rare exposure.

Authors:  David Hajage; Florence Tubach; Philippe Gabriel Steg; Deepak L Bhatt; Yann De Rycke
Journal:  BMC Med Res Methodol       Date:  2016-03-31       Impact factor: 4.615
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.